In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J)
Konstantinos Kalamatianos
Topics & Concepts
Virtual screeningIn silicoDrug repositioningChemistrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Binding affinitiesPharmacologyDocking (animal)RepurposingDrugDrug developmentCoronavirusAffinitiesAngiotensin-converting enzyme 2StereochemistryCombinatorial chemistryPharmacophoreComputational biologyCoronavirus disease 2019 (COVID-19)BiochemistryMedicineBiologyReceptorEcologyPathologyNursingInfectious disease (medical specialty)DiseaseGeneComputational Drug Discovery MethodsSynthesis and biological activitySARS-CoV-2 and COVID-19 Research